Effects of Graves' ophthalmopathy on quality of life

Journal of Endocrinological Investigation

Volumn 27, Issue 3, 2004, Pages 259-264

  Wiersinga, W M ^a   Prummel, M F ^a   Terwee, C B ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

GO QOL; Graves' ophthalmopathy; Quality of life

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHRONIC DISEASE; CLINICAL STUDY; COMORBIDITY; DECOMPRESSION SURGERY; DIABETES MELLITUS; DIPLOPIA; EMPHYSEMA; ENDOCRINE OPHTHALMOPATHY; EYE SURGERY; EYELID RECONSTRUCTION; HEART FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LANGUAGE; OUTCOMES RESEARCH; PSYCHOSOCIAL WITHDRAWAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RELIABILITY; SCORING SYSTEM; SELF EVALUATION; VALIDATION PROCESS; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 2342458239     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345275     Document Type: Article

References (25)

1. Terwee CB. Graves' ophthalmopathy through the eyes of the patient. Assessment of health-related quality of life. Ph.D. Thesis, University of Amsterdam, 2000.
2. Campbell A, Converse PE, Rodgers WL. The quality of American life. New York: Sage. 1976
3. Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996, 334: 835-40
4. Prummel MF, Mourits MPh, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993, 342: 949-54
5. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA 1995, 273: 59-65
6. Guyatt GH, Naylor D, Juniper E, et al. User's guides to the medical literature. XII. How to use articles about health-related quality of life? JAMA 1997, 277: 1232-7
7. Pinchera A, Wiersinga WM, Glinoer D, et al. Classification of eye changes of Graves' disease. Thyroid 1992, 2: 235-6
8. Prummel MF, Mourits MPh, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989, 321: 1353-9.
9. Kahn JA, Doane JF, Whitacre MM. Does compression diminish the discomfort of severe dysthyroid orbitopathy? Ophthalm Plast Reconstruct Surg 1995, 11: 109-12
10. Kung AWC, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid 1996, 6: 381-4
11. Fatourechi V, Garrity JA, Bartley GB, Bergstrahl EJ, DeSanto LW, Gorman CA. Results of transantral orbital decompression performed primarily for cosmetic indications. Ophthalmology 1994, 101: 938-42
12. Kane RL, Maciesjewski M, Finch M. The relationship of patient satisfaction with care and clinical outcomes. Med Care 1997, 35: 714-30
13. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473-83.
14. Aaronson NK, Muller M, Cohen PDA, et al. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 1998, 51: 1055-68.
15. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid 1997, 7: 885-9
16. Stewart AL, Greenfield S, Wells K, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989, 262: 907-13.
17. Kahaly GJ, Hardt J, Petrak F, Egle UT. Psychosocial factors in subjects with thyroid-associated ophthalmopathy. Thyroid 2002, 12: 237-39
18. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998, 82: 773-9
19. Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, Wiersinga WM. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy. J Clin Epidemiol 1999, 52: 875-84
20. Terwee CB, Dekker FW, Mourits MPh, et al. interpretation and validity of changes in scores in the GO-QOL after different treatments. Clin Endocrinol (Oxf) 2001, 54: 391-8
21. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989, 10: 407-15
22. Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves' ophthalmopathy in an incidence cohort. Ophthalmopathy 1996, 103: 958-62
23. Terwee CB, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga WM. Long-term effects of Graves' ophthalmopathy on health-related quality of life. Eur J Endocrinol 2002, 146: 751-7
24. Sprangers MAG, de Regt EB, Andries F, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 2000, 53: 895-907
25. Fayers P, Bjordal K. Should quality-of-life needs influence resource allocation? Lancet 2001, 357: 978